<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1">
<title>mCRPC Clinical Handbook (ASCO 2025)</title>

<style>
  body {
    font-family: "Trebuchet MS", sans-serif;
    margin: 0; padding: 0;
    background: #f7f9fb;
    color: #1a1a1a;
    line-height: 1.65;
  }
  header {
    background: #0b3d91;
    color: white;
    padding: 24px 16px;
    text-align: center;
  }
  h1 { margin: 0 0 8px; font-weight: 700; }
  h2 { margin-top: 40px; border-left: 5px solid #0b3d91; padding-left: 10px; }
  h3 { color: #0b3d91; margin-top: 28px; }
  .container { max-width: 900px; margin: auto; padding: 20px; }
  .section-card {
    background: white;
    border-radius: 12px;
    padding: 20px;
    margin: 22px 0;
    box-shadow: 0 2px 6px rgba(0,0,0,0.07);
  }
  .tag {
    display: inline-block;
    padding: 4px 10px;
    border-radius: 8px;
    color: white;
    font-size: 0.85rem;
    margin-right: 6px;
  }
  .arpi { background: #1976d2; }
  .parpi { background: #2e7d32; }
  .taxane { background: #d32f2f; }
  .radio { background: #6a1b9a; }
  .immuno { background: #ff8f00; }
  .other { background: #455a64; }

  .evidence-box {
    background: #eef4ff;
    border-left: 4px solid #0b3d91;
    padding: 10px 14px;
    margin-top: 12px;
    border-radius: 6px;
  }
  .trial {
    font-weight: bold;
    color: #0b3d91;
  }
  footer {
    text-align: center;
    color: #666;
    padding: 22px;
    margin-top: 40px;
  }
</style>
</head>

<body>

<header>
  <h1>mCRPC Clinical Handbook (ASCO 2025)</h1>
  <div>Evidence-informed systemic therapy recommendations with PFS/OS benefits and citations</div>
</header>

<div class="container">

<!-- INTRO -->
<section class="section-card">
  <h2>Introduction</h2>
  <p>
    This clinical handbook summarizes the 2025 ASCO guideline update for 
    <strong>metastatic castration-resistant prostate cancer (mCRPC)</strong>, integrating:
  </p>
  <ul>
    <li>Therapeutic selection based on <strong>prior castration-sensitive phase (CSPC) exposure</strong></li>
    <li><strong>HRR and MSI/MMR biomarkers</strong></li>
    <li>Clinical context (bone-only disease, indolent disease, oligoprogression)</li>
    <li><strong>PFS/OS benefits with trial citations</strong></li>
  </ul>

  <h3>Key Definitions</h3>
  <ul>
    <li><strong>mCRPC</strong> — Progression despite castrate testosterone (&lt;50 ng/dL), by radiographic or biochemical criteria.</li>
    <li><strong>HRR genes</strong> — BRCA1/2, PALB2, ATM, CHEK2, CDK12, etc.</li>
    <li><strong>MSI-H/dMMR</strong> — Predictive for immune checkpoint response.</li>
    <li><strong>Oligoprogression</strong> — Limited site progression (≤3 lesions) while overall disease is controlled.</li>
  </ul>

  <h3>Clinical Principles</h3>
  <ul>
    <li>Continue **ADT indefinitely**.</li>
    <li>Initiate **early palliative/supportive care**.</li>
    <li>Use **denosumab or zoledronic acid** for bone metastases.</li>
    <li>Avoid treatment changes for **PSA-only progression** without clinical/radiographic correlation.</li>
    <li>Imaging: **CT CAP + bone scan q3–6 months**.</li>
    <li>Use **PSMA PET** primarily to determine suitability for **¹⁷⁷Lu‑PSMA‑617**.</li>
  </ul>
</section>

<!-- BRANCH 1 -->
<section class="section-card">
  <h2>1. Patients Previously Treated With ADT Alone</h2>

  <h3>A. BRCA1/2 Positive → PARPi + ARPI</h3>
  <span class="tag parpi">PARPi</span>
  <span class="tag arpi">ARPI</span>
  <p><strong>Preferred regimens</strong>: olaparib + abiraterone; niraparib + abiraterone; talazoparib + enzalutamide.</p>

  <div class="evidence-box">
    <div class="trial">Evidence Summary</div>
    <ul>
      <li><strong>PFS:</strong> HR 0.28 (PROpel, TALAPRO‑2, MAGNITUDE BRCA subset)</li>
      <li><strong>OS:</strong> HR 0.47 (same pooled BRCA subset)</li>
      <li>Strongest benefit in BRCA1/2 vs other HRR</li>
    </ul>
    <div><strong>Citations:</strong> PROpel, TALAPRO‑2, MAGNITUDE</div>
  </div>

  <h3>B. Non-BRCA HRR → Talazoparib + Enzalutamide</h3>
  <span class="tag parpi">PARPi</span>
  <span class="tag arpi">ARPI</span>
  <div class="evidence-box">
    <ul>
      <li><strong>PFS:</strong> HR 0.71 (TALAPRO‑2 non‑BRCA subset)</li>
      <li><strong>OS:</strong> Not statistically significant</li>
    </ul>
    <div><strong>Citation:</strong> TALAPRO‑2</div>
  </div>

  <h3>C. HRR-Negative → Abiraterone / Enzalutamide / Docetaxel</h3>
  <span class="tag arpi">ARPI</span>
  <span class="tag taxane">Taxane</span>
  <div class="evidence-box">
    <ul>
      <li><strong>Abiraterone:</strong> PFS HR 0.52, OS HR 0.81 (COU‑AA‑302)</li>
      <li><strong>Enzalutamide:</strong> PFS HR 0.32, OS HR 0.77 (PREVAIL)</li>
      <li><strong>Docetaxel:</strong> OS HR 0.79 (TAX‑327)</li>
    </ul>
  </div>
</section>

<!-- BRANCH 2 -->
<section class="section-card">
  <h2>2. Patients Previously Treated With ADT + ARPI</h2>

  <h3>A. BRCA1/2 Positive → Olaparib Monotherapy</h3>
  <span class="tag parpi">PARPi</span>

  <div class="evidence-box">
    <ul>
      <li><strong>PFS:</strong> HR 0.22 (PROfound BRCA subset)</li>
      <li><strong>OS:</strong> HR 0.63</li>
    </ul>
    <div><strong>Citations:</strong> PROfound, TRITON‑3</div>
  </div>

  <h3>B. HRR– or Non-BRCA HRR → Docetaxel (Avoid ARPI→ARPI)</h3>
  <span class="tag taxane">Taxane</span>

  <div class="evidence-box">
    <ul>
      <li><strong>CARD trial:</strong> Cabazitaxel superior to abiraterone→enzalutamide or vice versa</li>
      <li><strong>PFS:</strong> 8.0 vs 3.7 months (HR 0.54)</li>
      <li><strong>OS:</strong> 13.6 vs 11.0 months (HR 0.64)</li>
    </ul>
  </div>
</section>

<!-- BRANCH 3 -->
<section class="section-card">
  <h2>3. Patients Previously Treated With ADT + Docetaxel</h2>

  <h3>A. HRR-positive → PARPi + ARPI if ARPI-naïve</h3>
  <span class="tag parpi">PARPi</span>
  <span class="tag arpi">ARPI</span>

  <div class="evidence-box">
    <ul>
      <li>Same benefits as BRCA1/2 subset in PROpel/TALAPRO‑2/MAGNITUDE</li>
    </ul>
  </div>

  <h3>B. HRR-negative → Abiraterone / Enzalutamide / Cabazitaxel</h3>
  <span class="tag arpi">ARPI</span>
  <span class="tag taxane">Taxane</span>

  <div class="evidence-box">
    <ul>
      <li><strong>Abiraterone post-docetaxel:</strong> PFS HR 0.66, OS HR 0.74 (COU‑AA‑301)</li>
      <li><strong>Enzalutamide post-docetaxel:</strong> OS HR 0.63 (AFFIRM)</li>
      <li><strong>Cabazitaxel:</strong> OS HR 0.70 (TROPIC)</li>
    </ul>
  </div>
</section>

<!-- BRANCH 4 -->
<section class="section-card">
  <h2>4. Patients Previously Treated With ADT + ARPI + Docetaxel (Triplet)</h2>

  <h3>A. PSMA-positive → ¹⁷⁷Lu‑PSMA‑617</h3>
  <span class="tag radio">Radiopharmaceutical</span>

  <div class="evidence-box">
    <ul>
      <li><strong>PFS:</strong> HR 0.40 (VISION)</li>
      <li><strong>OS:</strong> HR 0.62</li>
    </ul>
    <div><strong>Citation:</strong> VISION</div>
  </div>

  <h3>B. HRR-positive → Olaparib Monotherapy</h3>
  <span class="tag parpi">PARPi</span>

  <div class="evidence-box">
    <ul>
      <li><strong>PFS:</strong> HR 0.49 (PROfound HRR group)</li>
    </ul>
  </div>

  <h3>C. Symptomatic Bone-only → Radium‑223</h3>
  <span class="tag radio">Radiopharmaceutical</span>

  <div class="evidence-box">
    <ul>
      <li><strong>OS:</strong> HR 0.70 (ALSYMPCA)</li>
    </ul>
  </div>
</section>

<!-- SPECIAL -->
<section class="section-card">
  <h2>5. Special Clinical Situations</h2>

  <h3>Indolent, Minimally Symptomatic → Sipuleucel‑T</h3>
  <span class="tag other">Cellular therapy</span>

  <div class="evidence-box">
    <ul>
      <li><strong>OS benefit:</strong> HR 0.73</li>
      <li>No expected PSA or radiographic response</li>
    </ul>
    <div><strong>Citations:</strong> IMPACT, D9901, D9902A</div>
  </div>

  <h3>MSI-H/dMMR → Pembrolizumab</h3>
  <span class="tag immuno">Immunotherapy</span>

  <div class="evidence-box">
    <ul>
      <li><strong>ORR:</strong> ~40% across histology (KEYNOTE‑158)</li>
      <li>Modest prostate-specific sample size</li>
    </ul>
  </div>

  <h3>Oligoprogression → Metastasis-Directed Therapy (SBRT/Surgery)</h3>
  <span class="tag other">MDT</span>

  <div class="evidence-box">
    <ul>
      <li>Improved PFS when added to abiraterone in oligomet mCRPC</li>
    </ul>
    <div><strong>Citation:</strong> ARTO trial</div>
  </div>

  <h3>Neuroendocrine / Small-cell Variant → Platinum-based Therapy</h3>
  <span class="tag other">Platinum</span>
  <span class="tag taxane">Taxane</span>

  <div class="evidence-box">
    <ul>
      <li>Carboplatin/cisplatin + etoposide (SCLC-based paradigm)</li>
      <li>Carboplatin + cabazitaxel for AVPC phenotype</li>
    </ul>
  </div>
</section>

<footer>
  ASCO Guideline Update 2025 • mCRPC Systemic Therapy Handbook • Designed for quick clinical reference
</footer>
</div>

</body>
</html>
